1
|
Tiran AL, Claperon A, Davidson J, Starck JB, Diguarher TL, Chanrion M, Mistry P, Wang Y, Monceau E, Bernhardt F, Rocchetti F, Lysiak-Auvity G, Chen I, Daniels Z, Pedder C, Fallowfield M, Henlin JM, Fejes I, Tatai J, Nyerges M, Durand D, Zarka M, Sanghavi S, Girard AM, Schoumacher M, Kraus-Berthier L, Newcombe R, Halilovic E, Banquet S, Rupin A, Maacke H, Murray J, Morris E, Hofmann F, Colland F, Geneste O. Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Venetoclax (Venclexta™), a selective BCL-2 inhibitor, is the first member of a new class of anti-cancer drugs, called BH3 mimetics, to be approved for CLL and AML. Here, we describe the identification of a novel potent and selective BCL-2 inhibitor named S65487/VOB560 that has a different binding mode on BCL-2 compared to Venetoclax. This inhibitor binds to the BH3 hydrophobic groove of BCL-2. Its selectivity profile demonstrates lack of significant binding to MCL-1, BFL-1 and poor affinity for BCL-XL. S65487/VOB560 induces apoptosis in a panel of hematological cancer cell lines and inhibits cell proliferation with IC50s in the low nM range. S65487/VOB560 induces complete regression in BCL-2-dependent RS4;11 tumors in vivo after a single IV (intravenous) administration. Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat were observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665. These positive findings were further confirmed in a panel of AML PDX tumor models. Recently, acquired BCL-2 mutations (such as G101V and D103Y) were identified in patients with Chronic Lymphocytic Leukemia becoming resistant to Venetoclax. Interestingly, S65487/VOB560 is active on such BCL-2 mutants and induces apoptosis in preclinical resistance models. Altogether, these data demonstrate that S65487/VOB560 has significant therapeutic potential against human lymphoid and myeloid malignancies as well as in patients with Venetoclax resistant leukemias. Clinical studies are currently ongoing with S65487/VOB560 (NCT03755154).
Citation Format: Arnaud Le Tiran, Audrey Claperon, James Davidson, Jérôme-Benoit Starck, Thierry Le Diguarher, Maïa Chanrion, Prakash Mistry, Youzhen Wang, Elodie Monceau, Fabienne Bernhardt, Francesca Rocchetti, Gaelle Lysiak-Auvity, Ijen Chen, Zoe Daniels, Chris Pedder, Mandy Fallowfield, Jean-Michel Henlin, Imre Fejes, Janos Tatai, Miklos Nyerges, Didier Durand, Marion Zarka, Sneha Sanghavi, Anne-Marie Girard, Marie Schoumacher, Laurence Kraus-Berthier, Rick Newcombe, Ensar Halilovic, Sébastien Banquet, Alain Rupin, Heiko Maacke, James Murray, Erick Morris, Francesco Hofmann, Frédéric Colland, Olivier Geneste. Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1276.
Collapse
Affiliation(s)
- Arnaud Le Tiran
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Audrey Claperon
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Jérôme-Benoit Starck
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Thierry Le Diguarher
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Maïa Chanrion
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Prakash Mistry
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Youzhen Wang
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Elodie Monceau
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Fabienne Bernhardt
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Francesca Rocchetti
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Ijen Chen
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | - Zoe Daniels
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | | | | | - Jean-Michel Henlin
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Imre Fejes
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Janos Tatai
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Miklos Nyerges
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Didier Durand
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Marion Zarka
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Sneha Sanghavi
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Anne-Marie Girard
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Marie Schoumacher
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | | | - Rick Newcombe
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Ensar Halilovic
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Sébastien Banquet
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Alain Rupin
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Heiko Maacke
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | | | - Erick Morris
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Francesco Hofmann
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Frédéric Colland
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Olivier Geneste
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| |
Collapse
|
2
|
Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJ, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget 2018; 9:20075-20088. [PMID: 29732004 PMCID: PMC5929447 DOI: 10.18632/oncotarget.24744] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 02/26/2018] [Indexed: 12/15/2022] Open
Abstract
Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo, S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior. Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein.
Collapse
Affiliation(s)
- Patrick Casara
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | | | - Audrey Claperon
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Meike Vogler
- Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany
| | - Alain Bruno
- Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Maïa Chanrion
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Thierry Le Diguarher
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | - Jérôme-Benoît Starck
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | | | | | | | | | | | | | - Youzhen Wang
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | - Shumei Qiu
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | - Anne-Marie Girard
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Emilie Schneider
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Fabienne Gravé
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Aurélie Studeny
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Ghislaine Guasconi
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Sophie Maïga
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Jean-Michel Henlin
- Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France
| | - Frédéric Colland
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | | | - Steven Le Gouill
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Martin J.S. Dyer
- Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK
| | | | | | - Martine Amiot
- CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France
| | - Gerald M Cohen
- Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - John A. Hickman
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| | - Erick Morris
- Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA
| | | | - Olivier Geneste
- Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France
| |
Collapse
|
3
|
Audinot V, Zuana OD, Fabry N, Ouvry C, Nosjean O, Henlin JM, Fauchère JL, Boutin JA. S38151 [p-guanidinobenzoyl-[Des-Gly(10)]-MCH(7-17)] is a potent and selective antagonist at the MCH(1) receptor and has anti-feeding properties in vivo. Peptides 2009; 30:1997-2007. [PMID: 19619599 DOI: 10.1016/j.peptides.2009.07.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2009] [Revised: 06/21/2009] [Accepted: 07/10/2009] [Indexed: 11/19/2022]
Abstract
Structure-activity relationships studies have established the minimal sequence of melanin-concentrating hormone (MCH) that retains full agonist potency at the MCH(1), to be the dodecapeptide MCH(6-17). The alpha-amino function is not required for activity since arginine(6) can be replaced by p-guanidinobenzoyl, further improving activity. We report that the deletion of glycine in this short potent agonist (EC(50) 3.4nM) turns it into a potent and new MCH(1) antagonist (S38151, K(B) 4.3nM in the [(35)S]-GTPgammaS binding assay), which is selective versus MCH(2). A compared Ala-scan of the agonist and antagonist sequences reveals major differences in the residues that are mandatory for affinity, including arginine(11) and tyrosine(13) for the agonist and leucine(9) for the antagonist, whereas methionine(8) was necessary for both agonist and antagonist activities. A complete molecular study of the antagonist behavior is described in the present report, with a particular focus on the description of several analogues, attempting to find structure-activity relationships. Finally, S38151 antagonizes food intake when injected intra-cerebroventricularly in the rat. This is in agreement with the in vitro data and with our previous demonstration of a good correlation between in vitro and in vivo data on MCH(1) agonists.
Collapse
Affiliation(s)
- Valérie Audinot
- Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Henlin JM, Boutin JA, Duchêne-Roger F, Nicolas JP, Desmet-Beaufort C, Levens N, Fauchère JL. Parallel synthesis and pharmacological screening of nonpeptide ligands of the neuropeptide Y receptor subtype Y5. ACTA ACUST UNITED AC 2002; 57:419-27. [PMID: 11350602 DOI: 10.1034/j.1399-3011.2001.00766.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Several series of low-molecular-mass ligands of the neuropeptide receptor subtype Y5 were prepared using a mixed strategy of synthesis on solid phase and in solution. Collections of single compounds were obtained by an automated parallel procedure which allowed quick variation and investigation of the central spacer moiety, as well as of the aromatic substituents on each side. The strategy of parallel synthesis and screening of partially purified analogs helped to select rapidly potent and selective leads which displayed comparable antagonistic potency against neuropeptide Y activity on the Y5 receptor and better receptor selectivity than the original reference compounds.
Collapse
Affiliation(s)
- J M Henlin
- Institut de Recherches Servier, Suresnes, France; Institut de Recherches Servier, Croissy sur Seine, France
| | | | | | | | | | | | | |
Collapse
|
5
|
Henlin JM, Boutin JA, Kucharczyk N, Desmet-Beaufort C, Loynel A, Bertrand M, Genton A, Tucker GC, Atassi G, Fauchére JL. From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors. J Pept Res 2001; 57:85-96. [PMID: 11168892 DOI: 10.1034/j.1399-3011.2001.00787.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A complete 331,776-member library of tetrapeptides made of 24 amino acid building blocks was synthesized robotically on solid phase and subjected to a deconvolution based on the inhibitory potency of the sublibraries in a HPLC assay of the S-farnesyltransferase activity in vitro. One of the non-natural peptide and noncysteine-containing leads Nip-Trp-Phe-His (Nip=p-nitrophenyl-L-alanine) was optimized chemically to give a proteolytically stable pseudopeptide with a 200-fold potency compared with the original lead. The final compound was converted to the C-terminal ethyl ester: p-F-C6H4-CO(CH2)2-CO-Bta-D-Phepsi[CH2NH]His-OEt (Bta = benzothienyl-L-alanine) and shown to behave as a prodrug which was hydrolyzed back to the C-terminal acid following cell penetration. The method confirmed that several structurally original leads can be discovered in large libraries when deconvolution relies upon a highly specific assay and that these leads can be optimized by chemical modification to impart the final compound the desired pharmacological and pharmacokinetic properties.
Collapse
Affiliation(s)
- J M Henlin
- Institut de Recherches Servier, Suresnes, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E, Boutin JA. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275:31311-7. [PMID: 10913150 DOI: 10.1074/jbc.m005141200] [Citation(s) in RCA: 388] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The regulation of the circadian rhythm is relayed from the central nervous system to the periphery by melatonin, a hormone synthesized at night in the pineal gland. Besides two melatonin G-coupled receptors, mt(1) and MT(2), the existence of a novel putative melatonin receptor, MT(3), was hypothesized from the observation of a binding site in both central and peripheral hamster tissues with an original binding profile and a very rapid kinetics of ligand exchange compared with mt(1) and MT(2). In this report, we present the purification of MT(3) from Syrian hamster kidney and its identification as the hamster homologue of the human quinone reductase 2 (QR(2), EC ). Our purification strategy included the use of an affinity chromatography step which was crucial in purifying MT(3) to homogeneity. The protein was sequenced by tandem mass spectrometry and shown to align with 95% identity with human QR(2). After transfection of CHO-K1 cells with the human QR(2) gene, not only did the QR(2) enzymatic activity appear, but also the melatonin-binding sites with MT(3) characteristics, both being below the limit of detection in the native cells. We further confronted inhibition data from MT(3) binding and QR(2) enzymatic activity obtained from samples of Syrian hamster kidney or QR(2)-overexpressing Chinese hamster ovary cells, and observed an overall good correlation of the data. In summary, our results provide the identification of the melatonin-binding site MT(3) as the quinone reductase QR(2) and open perspectives as to the function of this enzyme, known so far mainly for its detoxifying properties.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Benzoquinones/metabolism
- Binding Sites
- Binding, Competitive
- CHO Cells
- Chromatography, Affinity
- Cricetinae
- DNA, Complementary/metabolism
- Humans
- Kidney/metabolism
- Kinetics
- Ligands
- Mass Spectrometry
- Melatonin/metabolism
- Mesocricetus
- Molecular Sequence Data
- NAD(P)H Dehydrogenase (Quinone)/chemistry
- NAD(P)H Dehydrogenase (Quinone)/isolation & purification
- NAD(P)H Dehydrogenase (Quinone)/metabolism
- Receptors, Cell Surface/chemistry
- Receptors, Cell Surface/isolation & purification
- Receptors, Cell Surface/metabolism
- Receptors, Cytoplasmic and Nuclear/chemistry
- Receptors, Cytoplasmic and Nuclear/isolation & purification
- Receptors, Cytoplasmic and Nuclear/metabolism
- Receptors, Melatonin
- Sequence Homology, Amino Acid
- Transfection
Collapse
Affiliation(s)
- O Nosjean
- Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Félétou M, Rodriguez M, Beauverger P, Germain M, Imbert J, Dromaint S, Macia C, Bourrienne A, Henlin JM, Nicolas JP, Boutin JA, Galizzi JP, Fauchère JL, Canet E, Duhault J. NPY receptor subtypes involved in the contraction of the proximal colon of the rat. Regul Pept 1998; 75-76:221-9. [PMID: 9802413 DOI: 10.1016/s0167-0115(98)00072-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Experiments were designed to determine the receptor subtype(s) involved in the contraction of the rat proximal colon to NPY. In this tissue, mRNA of Y2 and Y4 NPY receptor subtypes were highly expressed, whereas Y5 mRNA levels were very low and Y1 mRNA levels were intermediate. NPY analogues induced contractions with the following order of potency: rPP > hPP = PYY = NPY = [Leu31,Pro34]NPY > NPY(2-36) = [D-Trp32]NPY > NPY(33-36). Responses to NPY, PYY and NPY(13-36) were not or partially affected by tetrodotoxin, in contrast to the responses to [Leu31,Pro34]NPY, rPP, hPP and [D-Trp32]NPY which were fully blocked. Atropine did not inhibit the contractions to NPY, PYY and [Leu31,Pro34]NPY but significantly affected those to NPY(13-36), [D-Trp32]NPY, rPP and hPP. The specific Y1 receptor antagonist BIBP 3226 was ineffective but JCF 104 and JCF 105 (two compounds with preferential affinity toward the hY5 receptor versus the hY1 or hY2 receptor) abolished the contractions provoked by the NPY analogues. These results suggest that NPY activates three receptor subtypes, a Y2 subtype possibly by a direct action on the smooth muscle cells, as well as a Y4 and a Y5 (or 'Y5-like') subtype which, respectively, release acetylcholine and an unknown neurotransmitter.
Collapse
Affiliation(s)
- M Félétou
- Département de Diabétologie, Institut de Recherches Servier, Suresnes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Boutin JA, Gesson I, Henlin JM, Bertin S, Lambert PH, Volland JP, Fauchère JL. Limitations of the coupling of amino acid mixtures for the preparation of equimolar peptide libraries. Mol Divers 1998; 3:43-60. [PMID: 9527476 DOI: 10.1023/a:1009602707067] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The standard method of peptide library synthesis involves coupling steps in which a single amino acid is reacted with a mixture of resin-bound amino acids. The more recently described positional scanning strategy (in which each position in the peptide sequence is occupied in turn by a single residue) is different since it involves the coupling of mixtures of amino acids to mixtures of resin-bound amino acids. In the present study, we analyze the compounds produced under these conditions measuring coupling rates and amounts of formed products, using mainly UV, HPLC, LC/MS and MS/MS techniques. Our data do not permit to conclude that the resulting libraries are complete. Indeed, our analytical data indicate that a large part of the di-, tri- and tetrapeptides synthesized with this method are not present in the final mixture. Although chemical compensation (in which poor coupling kinetics is compensated by a larger excess of the incoming amino acid) has been thought to counterbalance these biases, our experiments show that the compensation method does not take into account the crucial influence of the resin-bound amino acid and that even the dipeptide libraries obtained in this way are far from completeness. The present work provides strong evidence that the coupling of mixtures of amino acids to resin-bound residues, which is required by the positional scanning strategy, results in incomplete and/or non-equimolar libraries. It also clearly confirms that coupling rates in solid-phase peptide synthesis are dependent on the nature of both the incoming and the immobilized amino acid.
Collapse
Affiliation(s)
- J A Boutin
- Department of Peptide and Combinatorial Chemistry, Institut de Recherches SERVIER, Suresnes, France
| | | | | | | | | | | | | |
Collapse
|
9
|
Fauchère JL, Henlin JM, Boutin JA. Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Can J Physiol Pharmacol 1997. [DOI: 10.1139/y97-076] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
10
|
Fauchère JL, Henlin JM, Boutin JA. Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Can J Physiol Pharmacol 1997; 75:683-9. [PMID: 9276149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The method of combinatorial synthesis of peptide and nonpeptide libraries on solid phase is analyzed and the automation of the mix and divide key step described. A set of amino acids leading to a high molecular diversity is proposed as well as a number of scaffolds for the preparation of variable polyamide libraries. Adequacy of the resin bead quantities to library size and to the ratio of the synthesized peptide types is discussed. Examples of the use of capillary electrophoresis and of spectroscopic methods (MS, MS/MS, and NMR) for the analysis of the library content are given. The iterative deconvolution SURF (synthetic unrandomization of randomized fragments) is compared with positional scanning and the success of coupling of mixtures evaluated. It is concluded that extension of the original mix and divide method and the SURF deconvolution (as proposed by Houghten et al. Nature (London), 354: 84-86 1991) to nonpeptide libraries affords new leads that can be optimized towards useful therapeutics.
Collapse
Affiliation(s)
- J L Fauchère
- Institut de recherches Servier, Suresnes, France
| | | | | |
Collapse
|
11
|
Henlin JM, Jaekel K, Moser P, Rink H, Spieser E, Baschang G. Synthesis of Octameric Phosphodiesters of[3,3-Bis(hydroxymethyl)cyclobutyl]adenine and -Thymine as well as their Hybridization Properties. ACTA ACUST UNITED AC 1992. [DOI: 10.1002/anie.199204821] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Henlin JM, Jaekel K, Moser P, Rink H, Spieser E, Baschang G. Synthese octamerer Phosphodiester von [3,3-Bis(hydroxymethyl)cyclobutyl]adenin und -thymin sowie deren Hybridisierungseigenschaften. Angew Chem Int Ed Engl 1992. [DOI: 10.1002/ange.19921040436] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
13
|
Henlin JM, Rink H, Spieser E, Baschang G. Synthesis of 3-Adenyl- and 3-Thyminylcyclobutane-1,1-dimethanols and Their Homo-octameric Phosphodiesters. Helv Chim Acta 1992. [DOI: 10.1002/hlca.19920750216] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
14
|
Rubino A, Thomann H, Henlin JM, Schilling W, Criscione L. Endothelium-dependent relaxant effect of neurokinins on rabbit aorta is mediated by the NK1 receptor. Eur J Pharmacol 1992; 212:237-40. [PMID: 1318213 DOI: 10.1016/0014-2999(92)90335-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Several neurokinins, namely substance P, neurokinin A, neurokinin B, [beta-Ala8]neurokinin A-(4-10) and senktide, were tested on noradrenaline-precontracted rabbit aortic rings to characterize the receptor mediating their endothelium-dependent relaxant effect in this preparation. CP-96,345, the new nonpeptide antagonist selective for the NK1 receptor, was also studied. Substance P, neurokinin A and neurokinin B, in that order of potency, were effective in relaxing precontracted rings, indicating the involvement of the NK1 receptor; [beta-Ala8]neurokinin A-(4-10) and senktide, which are selective agonists for NK2 and NK3 receptors, respectively, had no significant relaxant effect. The relaxant effects of substance P, neurokinin A and neurokinin B were competitively antagonized by nanomolar concentrations of CP-96,345. These findings support the view that the NK1 receptor mediates the endothelium-dependent relaxant effect of the neurokinins in rabbit aorta.
Collapse
Affiliation(s)
- A Rubino
- Cardiovascular Research Department, Ciba-Geigy Ltd., Basle, Switzerland
| | | | | | | | | |
Collapse
|
15
|
Fritz H, Henlin JM, Tschamber T, Streith J, Riesen A, Zehnder M. Stereospecific Synthesis of 2-Oxazinyl-4-oxoazetidinecarbamates Starting from a 1,2-Diazepine. A new type of intramolecular transbenzoylation. Helv Chim Acta 1988. [DOI: 10.1002/hlca.19880710418] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
16
|
|